Cardiorenal protection with SGLT2: Lessons from the cardiovascular outcome trials

Volume: 12, Issue: 4, Pages: 279 - 293
Published: Dec 11, 2019
Abstract
Sodium glucose cotransporter 2 (SGLT2) inhibitors are a class of drugs that were primarily developed for the treatment of type 2 diabetes mellitus. However, these agents have shown to provide additional beneficial effects. We will discuss three main topics regarding the use of SGLT2 inhibitors: noncardiovascular effects, cardiovascular benefits, and novel clinical indications. Multiple clinical trials and preliminary studies across varying...
Paper Details
Title
Cardiorenal protection with SGLT2: Lessons from the cardiovascular outcome trials
Published Date
Dec 11, 2019
Volume
12
Issue
4
Pages
279 - 293
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.